COSM
Cosmos Health Inc.
COSM has the edge over NVO overall, supported by stronger modeled upside and stronger fundamentals.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
COSM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Weak |
COSM's revenue is currently healthy, but its profitability, cash flow and balance sheet are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
COSM PE Valuation
COSM has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 2.1x next year's earnings.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
COSM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
COSM has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
COSM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.10 | — |
| Q2 2026 | -$0.66 | +$0.38 |
| Q1 2026 | -$0.66 | +$0.43 |
| Q4 2025 | -$0.63 | +$0.54 |
| Q3 2025 | -$0.76 | +$1.70 |
| Q2 2025 | -$1.04 | +$1.24 |
| Q1 2025 | -$1.09 | +$1.13 |
| Q4 2024 | -$1.17 | +$0.98 |
| Q3 2021 | -$11.50 | -454% |
COSM is still losing money, but far less than before: $0.66 per share over the past year, against $25.00 at its worst in late 2019.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over COSM on earnings quality, reporting a profit while its opponent remains loss making.
COSM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $19M | +29% |
| Q1 2026 | $17.9M | +31% |
| Q4 2025 | $19.7M | +39% |
| Q3 2025 | $17.1M | +38% |
| Q2 2025 | $14.7M | +12% |
| Q1 2025 | $13.7M | -6% |
| Q4 2024 | $14.2M | -10% |
| Q3 2024 | $12.4M | -3.2% |
COSM's revenue has grown year over year for five quarters in a row: $19M last quarter, up 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -15% | +2.5 points |
| Q1 2026 | -12% | -6.1 points |
| Q4 2025 | -58% | +5.1 points |
| Q3 2025 | -11% | +7.4 points |
| Q2 2025 | -18% | +1 points |
| Q1 2025 | -6.1% | +6.5 points |
| Q4 2024 | -63% | +23 points |
| Q3 2024 | -18% | +5.5 points |
COSM's operating margin was −15% last quarter, up 2.5 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over COSM on profitability, with a higher operating margin.
COSM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.8M | -$549.4K |
| Q1 2026 | -$1.1M | -$879.6K |
| Q4 2025 | -$4.6M | -$697.9K |
| Q3 2025 | -$2.5M | -583% |
| Q2 2025 | -$1.2M | +$12.6K |
| Q1 2025 | -$198.8K | +$3.3M |
| Q4 2024 | -$3.9M | -532% |
| Q3 2024 | $511K | +$5.1M |
COSM has burned cash in almost every quarter: −$10M over the past year, against −$5M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over COSM on cash generation, producing positive trailing cash flow while its opponent burns cash.
COSM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +27% | +12.8M shares |
| 1 year | +130% | +33.9M shares |
| 3 years | +8337% | +59.2M shares |
| 5 years | +11227% | +59.4M shares |
COSM has 60M diluted shares, up 130% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q4 2023 | $201 |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over COSM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
COSM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2021 | 8.5x | High |
| Q4 2020 | 3.3x | Elevated |
| Q3 2020 | -0.3x | Net Cash |
| Q2 2020 | -1.1x | Net Cash |
| Q1 2020 | -1.9x | Net Cash |
| Q4 2019 | 0.6x | Very low |
COSM's net debt is about 8.5 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
COSM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.5 | Neutral |
| Stochastic | 31.7 | Neutral |
COSM's weekly RSI is 41 (neutral) and its Stochastic is 32 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
COSM PE vs Healthcare Sector
| Metric | COSM | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
COSM has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
COSM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.31 | 32% below |
| 20 week MA | $0.27 | 22% below |
| 50 week MA | $0.33 | 36% below |
| 100 week MA | $0.49 | 57% below |
| 200 week MA | $1.10 | 81% below |
COSM is in a downtrend: it's below all five of its weekly moving averages, and 81% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over COSM on trend strength, trading above more of its moving averages.
COSM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $62.5 | $127.5 | +104% |
| 2021 | $127.5 | $99.0 | -22% |
| 2022 | $99.0 | $6.40 | -94% |
| 2023 | $6.40 | $1.41 | -78% |
| 2024 | $1.41 | $0.68 | -52% |
| 2025 | $0.68 | $0.51 | -25% |
| 2026 YTD | $0.51 | $0.21 | -59% |
COSM has finished five years in a row lower, and it's down 59% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over COSM on returns for 2026, with the stronger performance.